Abstract
Background: BRCA-1/2 germline mutations are responsible for early onset breast cancer and familial association. The underlying causes of the characteristic phenotypic behavior are not completely understood, but mammary stem cells appear to have a key role in this process. Materials and Methods: We have investigated the presence of mammary stem / progenitor cells in normal tissues and in tumor tissues obtained from women with and without BRCA1/2 germline mutations by utilizing ALDH-1 immunohistochemistry. Results: Isolated ALDH-1 positive cells were found in 15/28 (54%) of breast cancer samples from women with BRCA 1 or 2 mutations and in 33 /51 (65%) of matched sporadic breast cancer cases (p=0.5949, Chi Square test). While mammary stem cells were also detected in non-malignant breast lesions, only 41% of the tissues contained ALDH-1 positive cells (p=0.0371, Chi Square test). In patients with BRCA germline mutations ALDH-1 positive cells were more common in p53 positive (p=0.0028, Chi Square test) tumors, in high grade (p=0.0796), and in larger tumors (p=0.0604), while no such association was seen in sporadic cancer cases. In our patients, the expression of ALDH-1 positive cells in breast cancer was neither associated with disease-free and overall survival, nor time to metastasis. Conclusion: Breast cancers from BRCA mutation carriers do not harbor more ALHD-1 positive cells than sporadic tumors, and their more aggressive phenotype can thus not be explained by an increased stem cell pool. The presence of ALDH-1 in normal breast tissue suggests that additional factors determine the biological behavior of mammary stem cells.
Keywords: ALDH-1, BRCA carrier, breast cancer, cancer stem cell, AldehydeDehydrogenase-1, Estrogen Receptor, Loss of Heterozygosity, Overall Survival, Purified Bovine Serum, Progression-Free Survival, Progesterone Receptor, Time-To-Metastasis
Current Cancer Drug Targets
Title: Presence of Intratumoral Stem Cells in Breast Cancer Patients with or without BRCA Germline Mutations
Volume: 12 Issue: 1
Author(s): C. F. Singer, P. Zabkova, C. Rappaport, D. Muhr, G. Pfeiler, D. Gschwantler-Kaulich, A. Fink-Retter, C. Staudigl, I. Walter, G. Hudelist, A.-C. Spiess and E. Kubista
Affiliation:
Keywords: ALDH-1, BRCA carrier, breast cancer, cancer stem cell, AldehydeDehydrogenase-1, Estrogen Receptor, Loss of Heterozygosity, Overall Survival, Purified Bovine Serum, Progression-Free Survival, Progesterone Receptor, Time-To-Metastasis
Abstract: Background: BRCA-1/2 germline mutations are responsible for early onset breast cancer and familial association. The underlying causes of the characteristic phenotypic behavior are not completely understood, but mammary stem cells appear to have a key role in this process. Materials and Methods: We have investigated the presence of mammary stem / progenitor cells in normal tissues and in tumor tissues obtained from women with and without BRCA1/2 germline mutations by utilizing ALDH-1 immunohistochemistry. Results: Isolated ALDH-1 positive cells were found in 15/28 (54%) of breast cancer samples from women with BRCA 1 or 2 mutations and in 33 /51 (65%) of matched sporadic breast cancer cases (p=0.5949, Chi Square test). While mammary stem cells were also detected in non-malignant breast lesions, only 41% of the tissues contained ALDH-1 positive cells (p=0.0371, Chi Square test). In patients with BRCA germline mutations ALDH-1 positive cells were more common in p53 positive (p=0.0028, Chi Square test) tumors, in high grade (p=0.0796), and in larger tumors (p=0.0604), while no such association was seen in sporadic cancer cases. In our patients, the expression of ALDH-1 positive cells in breast cancer was neither associated with disease-free and overall survival, nor time to metastasis. Conclusion: Breast cancers from BRCA mutation carriers do not harbor more ALHD-1 positive cells than sporadic tumors, and their more aggressive phenotype can thus not be explained by an increased stem cell pool. The presence of ALDH-1 in normal breast tissue suggests that additional factors determine the biological behavior of mammary stem cells.
Export Options
About this article
Cite this article as:
F. Singer C., Zabkova P., Rappaport C., Muhr D., Pfeiler G., Gschwantler-Kaulich D., Fink-Retter A., Staudigl C., Walter I., Hudelist G., Spiess A.-C. and Kubista E., Presence of Intratumoral Stem Cells in Breast Cancer Patients with or without BRCA Germline Mutations, Current Cancer Drug Targets 2012; 12 (1) . https://dx.doi.org/10.2174/156800912798888938
DOI https://dx.doi.org/10.2174/156800912798888938 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Expanding the Biotherapeutics Realm via miR-34a: “Potent Clever Little” Agent in Breast Cancer Therapy
Current Pharmaceutical Biotechnology Adenosine Receptors: What We Know and What We are Learning
Current Topics in Medicinal Chemistry Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation
Current Cancer Drug Targets Clinical Applications of <sup>18</sup>F-FDG PET/CT in Monitoring Anti-cancer Therapies
Current Pharmaceutical Biotechnology Synthesis and <i>In silico</i> Studies of Quinazolinone Derivatives as PARP-1 Inhibitors
Letters in Drug Design & Discovery Transcriptional Regulation by Promoter Targeted RNAs
Current Topics in Medicinal Chemistry Exploring miRNA Sponge Networks of Breast Cancer by Combining miRNA-disease-lncRNA and miRNA-target Networks
Current Bioinformatics Combination Treatment of Glioblastoma by Low-Dose Radiation and Genistein
Current Radiopharmaceuticals The Role of Mass Spectrometry in the “Omics” Era
Current Organic Chemistry Transcriptionomic Study on Apoptosis of SKOV-3 Cells Induced by Phycoerythrin from <i>Gracilaria lemaneiformis</i>
Anti-Cancer Agents in Medicinal Chemistry Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry Inhibition of TGF-β Signaling in Tumor Cells by Small Molecule Src Family Kinase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Recent Progress in the Development of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Staphylococcus aureus: The Toxic Presence of a Pathogen Extraordinaire
Current Medicinal Chemistry Targeting Heme for the Identification of Cytotoxic Agents
Anti-Cancer Agents in Medicinal Chemistry Is the Epithelial-to-Mesenchymal Transition Clinically Relevant for the Cancer Patient?
Current Pharmaceutical Biotechnology Cognitive Dysfunction in Depression – Pathophysiology and Novel Targets
CNS & Neurological Disorders - Drug Targets Omacetaxine as an Anticancer Therapeutic: What is Old is New Again
Current Pharmaceutical Design Do Advanced Glycation End Products (AGEs) Contribute to the Comorbidities of Polycystic Ovary Syndrome (PCOS)?
Current Pharmaceutical Design